Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer

被引：9

作者：

Deng, Jing ^{[1
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

来源：

BREAST CANCER RESEARCH | 2013年 / 15卷 / 05期

基金：

英国医学研究理事会;

关键词：

INHIBITOR; NAVITOCLAX; POTENT;

D O I：

10.1186/bcr3568

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The B-cell lymphoma/leukemia 2 protein (BCL-2) may help many types of cancers to evade cell death. However, identifying exactly where this is the case is a challenge. ABT-199 is a small molecule that selectively inhibits BCL-2, which is currently in clinical trials in lymphoid malignancies. While inhibiting BCL-2 by itself can cause cell death in hematopoietic tumors, single-agent activity is harder to observe in solid tumors. Combining ABT-199 with tamoxifen, the standard endocrine therapy for estrogen receptor-positive breast cancers, 85% of which have BCL-2 expression, represents a new strategy to prime cancer cells for apoptosis and elicit better cancer cell death responses.

引用

页数：2

共 15 条

[1]

ABT-199: Taking Dead Aim at BCL-2 [J].

Davids, Matthew S. ;

Letai, Anthony .

CANCER CELL, 2013, 23 (02) :139-141

[2]

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received [J].

Dawson, S-J ;

Makretsov, N. ;

Blows, F. M. ;

Driver, K. E. ;

Provenzano, E. ;

Le Quesne, J. ;

Baglietto, L. ;

Severi, G. ;

Giles, G. G. ;

McLean, C. A. ;

Callagy, G. ;

Green, A. R. ;

Ellis, I. ;

Gelmon, K. ;

Turashvili, G. ;

Leung, S. ;

Aparicio, S. ;

Huntsman, D. ;

Caldas, C. ;

Pharoah, P. .

BRITISH JOURNAL OF CANCER, 2010, 103 (05) :668-675

[3]

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents [J].

Deng, Jing ;

Carlson, Nicole ;

Takeyama, Kunihiko ;

Dal Cin, Paola ;

Shipp, Margaret ;

Letai, Anthony .

CANCER CELL, 2007, 12 (02) :171-185

[4]

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737 [J].

Moore, Victoria Del Gaizo ;

Brown, Jennifer R. ;

Certo, Michael ;

Love, Tara M. ;

Novina, Carl D. ;

Letai, Anthony .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) :112-121

[5]

Biological determinants of endocrine resistance in breast cancer [J].

Musgrove, Elizabeth A. ;

Sutherland, Robert L. .

NATURE REVIEWS CANCER, 2009, 9 (09) :631-643

[6]

Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 [J].

Oakes, Samantha R. ;

Vaillant, Francois ;

Lim, Elgene ;

Lee, Lily ;

Breslin, Kelsey ;

Feleppa, Frank ;

Deb, Siddhartha ;

Ritchie, Matthew E. ;

Takano, Elena ;

Ward, Teresa ;

Fox, Stephen B. ;

Generali, Daniele ;

Smyth, Gordon K. ;

Strasser, Andreas ;

Huang, David C. S. ;

Visvader, Jane E. ;

Lindeman, Geoffrey J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (08) :2766-2771

[7]

An inhibitor of Bcl-2 family proteins induces regression of solid tumours [J].

Oltersdorf, T ;

Elmore, SW ;

Shoemaker, AR ;

Armstrong, RC ;

Augeri, DJ ;

Belli, BA ;

Bruncko, M ;

Deckwerth, TL ;

Dinges, J ;

Hajduk, PJ ;

Joseph, MK ;

Kitada, S ;

Korsmeyer, SJ ;

Kunzer, AR ;

Letai, A ;

Li, C ;

Mitten, MJ ;

Nettesheim, DG ;

Ng, S ;

Nimmer, PM ;

O'Connor, JM ;

Oleksijew, A ;

Petros, AM ;

Reed, JC ;

Shen, W ;

Tahir, SK ;

Thompson, CB ;

Tomaselli, KJ ;

Wang, BL ;

Wendt, MD ;

Zhang, HC ;

Fesik, SW ;

Rosenberg, SH .

NATURE, 2005, 435 (7042) :677-681

[8]

Mechanisms of tamoxifen resistance [J].

Ring, A ;

Dowsett, M .

[9]

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease [J].

Roberts, Andrew W. ;

Seymour, John F. ;

Brown, Jennifer R. ;

Wierda, William G. ;

Kipps, Thomas J. ;

Khaw, Seong Lin ;

Carney, Dennis A. ;

He, Simon Z. ;

Huang, David C. S. ;

Xiong, Hao ;

Cui, Yue ;

Busman, Todd A. ;

McKeegan, Evelyn M. ;

Krivoshik, Andrew P. ;

Enschede, Sari H. ;

Humerickhouse, Rod .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :488-496

[10]

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].

Sorlie, T ;

Perou, CM ;

Tibshirani, R ;

Aas, T ;

Geisler, S ;

Johnsen, H ;

Hastie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Thorsen, T ;

Quist, H ;

Matese, JC ;

Brown, PO ;

Botstein, D ;

Lonning, PE ;

Borresen-Dale, AL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874

← 1 2 →